rosuvastatin
AssetSmall moleculeAlso AZD4522, rosuvastatin calcium, YN001, Rosuvastatin calcium Tablets
HMG-CoA reductase inhibitor lowering LDL cholesterol.
- Stage
- Approved
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- Indications
- 59
- Trials
- 488
- Developers
- 15
Indications
60No named disease
Approvedaccessdata.fda.gov7 Oct 2026
Acute coronary syndrome
Phase 3COMPLETEDNCT00296387clinicaltrials.gov7 Oct 2026
Atherosclerosis
Phase 3COMPLETEDNCT02546323clinicaltrials.gov7 Oct 2026
57 more
- Targets and what it contains3
- Owner and partners15
- Trials488
- Evidence for its targets4
- Competitors12
- Aging relevance1
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 81 sources